Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Inks Deal to Distribute Luminex Assay Instruments

NEW YORK (GenomeWeb) – Affymetrix and Luminex today announced a distribution agreement for eBioscience, an Affymetrix subsidiary, to distribute Luminex's Magpix, Luminex 200, and Flexmap 3D multiplexed assay platforms.

Under the terms of the agreement, Affymetrix will sell those platforms alongside the eBioscience Luminex ProcartaPlex immunoassays and Panomics QuantiGene Plex gene expression assays, in the US, Canada, Mexico, Brazil, China, the Netherlands, Germany, France, the UK, Switzerland, Austria, Belgium, Ireland, Luxembourg, and Poland.

Financial terms of the agreement were not disclosed.

"This agreement deepens our relationship with Luminex and will provide our customers an integrated solution to access a best-in-class platform with an ever-expanding, high-quality assay menu," Dara Grantham Wright, Affymetrix senior VP and general manager of eBioscience, said in a statement.

The link between the two firms goes back several years. In 2008, Affymetrix acquired a menu of assays for the Luminex platform when it bought Panomics. After acquiring eBio in 2012, Affymetrix began moving those immunoassays to the Luminex xMap platform.

Luminex VP of global sales and customer operations Todd Bennett said the deal would help customers access instruments and assays for disease-related research around the world.

Shares of Affymetrix were up 2 percent to $8.50 in morning trading on the Nasdaq.

This story orignally indicated that the ProcartaPlex immunoassay was a Luminex product. It has been corrected to recognize that Affymetrix subsidiary eBioscience makes the product called the Luminex ProcartaPlex assay.